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Abstract 30 
Heat Shock Factor 1 (HSF1) monitors the structural integrity of the proteome. 31 
Phosphorylation at S326 is a hallmark for HSF1 activation, but the identity of the 32 
kinase(s) phosphorylating this site has remained elusive. We show that the dietary 33 
agent phenethyl isothiocyanate (PEITC) inhibits heat shock protein 90 (Hsp90), the 34 
main negative regulator of HSF1, activates p38 MAPK, increases S326 35 
phosphorylation, trimerization and nuclear translocation of HSF1, and the 36 
transcription of a luciferase reporter as well as the endogenous prototypic HSF1 target 37 
Hsp70. In vitro, all members of the p38 mitogen-activated protein kinase (MAPK) 38 
family rapidly and stoichiometrically catalyze the S326 phosphorylation. The use of 39 
stable knockdown cell lines and inhibitors indicated that among the p38 MAPK, p38γ 40 
is the principal isoform responsible for the phosphorylation of HSF1 at S326 in cells. 41 
A protease-mass spectrometry approach confirmed S326 phosphorylation, and 42 
unexpectedly, revealed that p38 MAPK also catalyze phosphorylation of HSF1 at 43 
S303/307, previously known repressive post-translational modifications. Thus, we 44 
have identified p38 MAPK as highly efficient catalysts for the phosphorylation of 45 
HSF1. Furthermore, our findings suggest that the magnitude and persistence of 46 
activation of p38 MAPK are important determinants of the extent and duration of the 47 
heat shock response. 48 
  49 
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Introduction 50 
Heat Shock Factor 1 (HSF1) orchestrates an elaborate transcriptional program which 51 
enhances adaptation and survival under conditions of stress. It is activated in response 52 
to stresses such as heat shock, hypoxia, heavy metals, reactive oxygen species and 53 
changes in pH. In an unstressed system, monomeric HSF1 is bound to its negative 54 
regulators, heat shock proteins (Hsp) 40, 70 and 90 (1-3). During stress, HSF1 is 55 
released from the complex, and undergoes several activating post-translational 56 
modifications that allow it to form a transcriptionally active trimer. In the nucleus, 57 
trimeric HSF1 binds to heat shock elements (HSE, comprising the consensus inverted 58 
repeat sequences nGAAn) to orchestrate transcription of large networks of 59 
cytoprotective genes, including molecular chaperones, DNA damage repair 60 
components, and metabolic enzymes (4). Activation of HSF1 plays a vital role in 61 
human physiology and ageing, as well as in pathological processes such as 62 
cardiovascular disease, neurodegeneration, and cancer.  63 
Increased nuclear HSF1 levels correlate with poor prognosis in breast, colon 64 
and lung cancer (5, 6). Furthermore, it is becoming increasingly clear that HSF1 is 65 
able to support the malignant phenotype by orchestrating a transcriptional program 66 
beyond the heat shock response, including energy metabolism (5, 7). In addition, 67 
some of the downstream target genes of HSF1 encode proteins involved in global 68 
protein translation, such as the RNA-binding protein HuR (8, 9). Santagata et al. (10) 69 
have reported that inhibition of protein translation in malignant cells reduced the 70 
activation of HSF1, providing an insight that a close relationship exists between the 71 
translational machinery and the transcriptional program orchestrated by HSF1. These 72 
findings raise the possibility of targeting HSF1 by inhibiting the cellular processes 73 
that lead to activation of the transcription factor in cancer.  74 
The activity of HSF1 is controlled by a wide range of post-translational 75 
modifications. Westerheide et al. (11) have reported that activation of the deacetylase 76 
and longevity factor SIRT1 maintains HSF1 in a deacetylated, DNA-binding 77 
competent state, and extends the duration of the heat shock response. Raychaudhuri et 78 
al. (12) discovered that EP300/CREB, a histone acetyltransferase, is responsible for 79 
stabilization of HSF1 through acetylation of several of its lysine residues. In addition 80 
to acetylation, various phosphorylation modifications cause the transcription factor to 81 
become either transcriptionally repressed or activated. Most phosphorylation 82 
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modifications occur within the regulatory domain (RD) of HSF1 and are inhibitory. 83 
Indeed, a recent study has shown that a phosphorylation-deficient HSF1 mutant, in 84 
which the 15 known phosphorylation sites within the RD had been disrupted 85 
(HSF1ΔpRD), is a potent transactivator under stress conditions, and has a lower 86 
activation threshold than its wild-type counterpart (13). In human HSF1, 87 
phosphorylation at S303 [PPS303PPQS307PRV] after obligatory priming 88 
phosphorylation at S307 by the mitogen-activated protein kinase (MAPK) ERK1, is 89 
carried out by glycogen synthase kinase (GSK)3, inhibiting the function of the 90 
transcription factor (14-17). Similarly, phosphorylation at S121, catalyzed by MAPK-91 
activated protein kinase 2 (MK2), inhibits the transcriptional activity of HSF1 and 92 
promotes its binding to Hsp90 (18). In stark contrast, phosphorylation at S326 93 
[VDTLLS326PTAL] activates HSF1, and the mutation of S326 to alanine (S326A) 94 
reduces its transcriptional activity by more than 80% (19, 20). To our knowledge, the 95 
identity of the kinase(s) phosphorylating this site has not been clearly established.  96 
Diets rich in cruciferous vegetables have protective effects against 97 
neurodegenerative and cardiovascular disease, and cancer (21). Watercress 98 
(Nasturtium officinale), a vegetable from this family, is a rich source of the 99 
glucosinolate gluconasturtiin. Phenethyl isothiocyanate (PEITC) (Fig. 1A) is an 100 
isothiocyanate (ITC) that forms during plant tissue injury from gluconasturtiin, 101 
through the catalytic action of myrosinase [E.C. 3.2.1.147], a β-thioglucosidase (22, 102 
23). PEITC is currently in clinical trials for prevention of lung cancer and for 103 
depletion of oral cells expressing mutant p53 in people who smoke 104 
(ClinicalTrials.gov). Due to the presence of the electrophilic isothiocyanate group, 105 
which reacts readily with sulfhydryl groups, PEITC is an activator of transcription 106 
factor nuclear factor-erythroid 2 p45-related factor 2 (NRF2), a master transcriptional 107 
regulator of antioxidant, anti-inflammatory, and drug-metabolizing enzymes. Global 108 
gene expression profiling of murine liver has revealed that, in addition to classical 109 
NRF2-dependent genes, a single dose (40 mg/kg) of orally-administered PEITC 110 
induces transcription of heat shock proteins (24), but how this occurs is not known. 111 
Interestingly, PEITC has been reported to activate signal transduction cascades, 112 
including protein kinases (25). Here we show that PEITC activates p38 MAPK, 113 
causes phosphorylation of HSF1 at S326, and transcriptionally activates HSF1. We 114 
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further identify the family of p38 MAPK as highly efficient catalysts of the 115 
phosphorylation of HSF1. 116 
 117 
Results 118 
Cysteine-reactive PEITC induces the heat shock response.  We have previously 119 
reported that structurally diverse NRF2 activators, all of which react with sulfhydryl 120 
groups, induce the heat shock response, and demonstrated the essential requirement 121 
for HSF1 (26). The isothiocyanates represent a prominent class of NRF2 activators, 122 
which have shown chemoprotective effects in numerous animal models of chronic 123 
disease; some have been and/or currently are in clinical trials (27-29). We therefore 124 
examined the potential heat shock response-inducer activity of three representative 125 
isothiocyanates: allyl- (AITC), benzyl- (BITC), and phenethyl isothiocyanate 126 
(PEITC) (Fig. 1A) in the human breast cancer cell line MDA-MB-231, using Hsp70 127 
as a prototypic heat shock protein. When cells were exposed for 24 h to the aromatic 128 
isothiocyanates BITC or PEITC at a concentration of 10 μM, the levels of Hsp70 129 
increased by ~12- and ~10-fold, respectively, whereas the levels of Hsp70 remained 130 
unchanged upon exposure to 10 μM of the aliphatic isothiocyanate AITC (Fig. 1B). 131 
PEITC is in clinical trials for prevention of lung cancer and for depletion of oral cells 132 
expressing mutant p53 (ClinicalTrials.gov). We therefore focused our subsequent 133 
studies on this isothiocyanate. Experiments in mouse embryonic fibroblasts (MEFs) 134 
confirmed the requirement for HSF1 for the induction of Hsp70 by PEITC. In wild-135 
type MEFs, exposure to 7.5- or 10 μM PEITC for 24 h caused an upregulation of 136 
Hsp70 by ~2- and ~3.2-fold, respectively, whereas the levels of this heat shock 137 
protein remained unchanged in their HSF1-deficient counterparts (Fig. 1C). 138 
Consistent with the increase in the protein levels of Hsp70, the mRNA levels for 139 
hspa1a were upregulated by 4.1- and 3.5-fold after exposure of wild-type MEF cells 140 
to 10 μM PEITC for 8- or 16 h, respectively (Fig. 1D). 141 
Nuclear-cytoplasmic separation experiments conducted in MDA-MB-231 142 
cells showed that PEITC caused nuclear translocation of HSF1 (Fig. 1E). Thus, in 143 
vehicle-treated cells, HSF1 was present in both the cytoplasmic and nuclear fractions. 144 
In sharp contrast, in the cytoplasmic fraction of cells treated with PEITC for 3 h, there 145 
was no detectable HSF1, and essentially all HSF1 was in the nuclear fraction. 146 
Furthermore, the presence of monomeric, dimeric and trimeric HSF1 species was 147 
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readily detectable in the nuclear fraction of PEITC-treated cells. Collectively, these 148 
experiments show that upon PEITC treatment, HSF1 undergoes nuclear translocation 149 
and trimerization. Notably, the gel electrophoretic mobility of monomeric HSF1 in 150 
the nuclear fraction of PEITC-treated cells was slower than in their vehicle-treated 151 
counterparts (Fig. 1E), indicative of occurrence of post-translational modifications. 152 
Trimerization is required for the transcriptional activity of HSF1 (30-33). To 153 
test whether the HSF1 trimers that form upon treatment with PEITC are able to 154 
enhance transcription through heat shock elements (HSEs), we used the cervical 155 
cancer HeLa HSE-luciferase reporter cell line (HeLa-HSE-luc) stably transfected with 156 
the HSP70.1 promoter fused to the luciferase gene (34). Remarkably, PEITC led to a 157 
dramatic dose- and time-dependent induction of the reporter, with a maximal increase 158 
of more than 1000-fold (Fig. 1F). Together, these results demonstrate that PEITC is a 159 
potent and robust inducer of the heat shock response. 160 
 161 
PEITC inhibits Hsp90. Activation of HSF1 requires release from its negative 162 
regulators; indeed, inhibition of Hsp90, the main negative regulator of HSF1, often 163 
leads to induction of the heat shock response (35). To test whether PEITC inhibits the 164 
function of Hsp90, we evaluated the stability of two well-established Hsp90 client 165 
oncoproteins, the tyrosine kinase HER2 and the serine/threonine kinase RAF1, both 166 
of which bind strongly to Hsp90 (36). After treatment with PEITC, the levels of 167 
HER2 and RAF1 were decreased by ~60- and ~35%, respectively, consistent with 168 
Hsp90 inhibition (Fig. 2A). Treatment with 10 μM PEITC did not lead to any changes 169 
in the transcription of either of these genes, as quantified by real-time PCR. 170 
Interestingly however, the 20- μM PEITC treatment led to a significant (p = 0.002, n 171 
= 3) 45% decrease in the mRNA levels for HER2, although the mRNA levels for 172 
RAF1 were not affected (not shown). The reason for this decrease in HER2 173 
expression, and its potential contribution to the decreased HER2 protein levels at the 174 
high concentration of PEITC is presently unknown. In contrast to geldanamycin (GA), 175 
an Hsp90 inhibitor that competes with ATP, but similarly to celastrol (CL) and 176 
sulfoxythiocarbamate alkyne (STCA), which inhibit Hsp90 by modifying its cysteine 177 
residues without interfering with ATP binding (37), PEITC did not prevent the ability 178 
of the chaperone to bind ATP (Fig. 2B). These results support the notion that PEITC, 179 
by virtue of its cysteine reactivity inhibits Hsp90, and further suggest that, by 180 
inhibiting Hsp90, the isothiocyanate may trigger the release of HSF1. Indeed, 181 
 7
immunoprecipitation experiments showed that the amount of HSF1 bound to Hsp90 is 182 
greatly reduced upon exposure to PEITC (Fig. 2C). 183 
 184 
PEITC causes phosphorylation of HSF1 at S326. In addition to release from Hsp90, 185 
full transcriptional activation of HSF1 requires its phosphorylation at S326 (19, 20). 186 
The shift in gel electrophoretic mobility of the monomeric form of HSF1 in nuclear 187 
fractions of PEITC-treated cells (Fig. 1D) indicated the occurrence of post-188 
translational modifications. Given the dramatic activation of the HSE-luciferase 189 
reporter by PEITC (Fig. 1F), we tested the possibility that exposure to PEITC was 190 
causing HSF1 phosphorylation at S326. The use of a pS326-phosphospecific antibody 191 
revealed a time- and dose-dependent increase in pS326 HSF1 and an upregulation of 192 
Hsp70 upon exposure to PEITC (Fig. 3A). Notably and in full agreement with the 193 
shift in electrophoretic mobility of HSF1 in nuclear fractions of PEITC-treated cells 194 
(Fig. 1D) as well as in the immunoprecipitation experiment (Fig. 2C), in this 195 
experiment the migration of HSF1 was slower in lysates from cells treated with 20 196 
μM PEITC than from vehicle- or 10 μM PEITC-treated cells (Fig. 3A). Surprisingly 197 
however, although HSF1 S326 phosphorylation was more extensive upon treatment 198 
with the higher concentration (20 μM) of PEITC, induction of Hsp70 appeared to be 199 
greater at the lower concentration (10 μM) of the isothiocyanate. Nuclear-cytoplasmic 200 
separation further confirmed the accumulation of pS326 HSF1 in both cytoplasmic 201 
and nuclear fractions (Fig. 3B). The results from this shorter time-course experiment 202 
also indicated that HSF1 phosphorylation occurred in the cytoplasm and preceded the 203 
nuclear translocation of the transcription factor. 204 
 205 
PEITC activates p38 MAPK. S326 of HSF1 represents a proline-directed 206 
phosphorylation site. Only a stringent subset of kinases, known as CMGC kinases are 207 
able to phosphorylate proline-directed sites (38). As PEITC has been reported to 208 
activate p38 mitogen-activated protein kinases (MAPK) (25), a proline-directed 209 
family of kinases, we next examined their status in MDA-MB-231 cells. A dose-210 
dependent phosphorylation of p38 MAPK was readily detectable, and increased by 211 
~30- and ~90-fold, after treatment with 10- and 20 μM of PEITC, respectively (Fig. 212 
4A). Importantly, the levels of p38 MAPK were unchanged, showing that PEITC did 213 
not cause any alterations in protein expression or stability of the kinases. In contrast to 214 
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the activation of p38 MAPK, exposure to PEITC decreased the phosphorylation of the 215 
ribosomal subunit S6 at S235/236 (Fig. 4B), indicating inhibition of the mechanistic 216 
target of rapamycin (mTOR), a kinase that had been previously implicated in the 217 
phosphorylation of HSF1 at S326 (20). Moreover, the dose-dependent PEITC-218 
mediated phosphorylation of p38 MAPK correlates well with the extent of 219 
phosphorylation of HSF1 at S326, which increased by 30- and 55-fold, after treatment 220 
with 10- and 20 μM PEITC, respectively (Fig. 4A).  221 
It has been reported that the c-Jun N-terminal kinases (JNK) phosphorylate 222 
and activate HSF1 (39). We therefore next tested the effect of JNK-In-8, a JNK-223 
selective inhibitor (40) and BIRB0796, a p38 MAPK inhibitor (41), on the ability of 224 
PEITC to induce phosphorylation of HSF1 at S326. Both inhibitors decreased the 225 
PEITC-mediated phosphorylation of HSF1 at S326 (Fig. 4C). However, a time course 226 
experiment further revealed that, although both p38 and JNK1/2 were activated by 227 
exposure to 20 μM PEITC, the activation of JNK1/2 displayed a delayed kinetics in 228 
comparison with the kinetics of activation of p38 MAPK (Fig. 4D).  229 
Recently, it was reported that HSF1 physically interacts and is phosphorylated 230 
at S326 by MAPKK (also known as MEK) (42). We therefore next examined the 231 
effect of inhibiting MEK on HSF1 S326 phosphorylation using the highly selective 232 
MEK1/2 inhibitor 1,4-diamino-2,3-dicyano-1, 4-bis[2-aminophenylthio]butadiene 233 
(U0126) (43). In agreement with the published report (42), we were able to detect 234 
reduced levels of phosphorylation of HSF1 at S326 in lysates of heat-shocked cells 235 
that had been pre-treated for 24 h with U0126 (Fig. 5A). However, the MEK inhibitor 236 
had no effect on the phosphorylation of HSF1 at S326 in heat-shocked cells that had 237 
been pre-treated with U0126 for 1 h (Fig. 5B). Overall, these findings raise the 238 
possibility that p38 MAPK could represent one group of the long-sought catalysts for 239 
the phosphorylation of this key residue. 240 
 241 
p38 MAPK phosphorylate HSF1 at S326 in vitro. Next, we used recombinant HSF1 242 
to test the ability of purified recombinant p38 MAPK isoforms to phosphorylate 243 
HSF1 in vitro. HSF1 was expressed as a His-tagged fusion protein in Escherichia coli. 244 
Purified His-HSF1 migrated as a major band during NuPAGE® at the expected 245 
molecular weight, and showed a tendency to form spontaneously dimeric and trimeric 246 
species (Fig. 6A). The four p38 MAPK isoforms (α, β, γ and δ) were expressed 247 
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individually in Escherichia coli from human cDNAs as inactive GST-fusion proteins, 248 
and purified by affinity chromatography on glutathione-Sepharose. Recombinant 249 
MKK6 was then used to activate the p38 proteins, and subsequently removed by 250 
passage through amylose resin. The enzyme activity of each p38 isoform was 251 
quantified by the phosphorylation of a standard substrate, myelin basic protein. Each 252 
kinase was used at an equivalent specific enzyme activity in reactions with HSF1 as a 253 
substrate.  254 
All p38 isoforms were able to rapidly phosphorylate HSF1 (Fig. 6B, black 255 
bars). Quantitative analysis of incubation reactions of HSF1 with either p38α, 256 
p38β, p38γ or p38δ and Mg-[γ32P]-ATP revealed that p38δ phosphorylated HSF1 at a 257 
higher rate and stoichiometry than did p38α, p38β or p38γ, indicating that HSF1 is a 258 
better substrate for p38δ than for any of the other p38 isoforms (Fig. 6B, black bars 259 
and Fig. 6C). Parallel reactions in the absence of HSF1 showed that, under these 260 
experimental conditions, there was no detectable autophosphorylation of any of the 261 
kinases (not shown), and the radioactivity in these samples (as quantified by 262 
scintillation counting) was identical to that of the buffer blank. Western blot analysis 263 
using the S326-posphospecific antibody confirmed this conclusion and clearly 264 
demonstrated that S326 was one of the phosphorylation sites (Fig. 6D).  265 
The extent of phosphorylation of HSF1 was dependent on the kinase 266 
concentration as well as the incubation time. Thus, with 6 mU/μl of enzyme and 60 267 
min incubation (when phosphate incorporation had reached or was approaching a 268 
plateau), the stoichiometry of the reaction was 2, 1.3, 0.8, and 2.2 mol/mol for the 269 
α, β, γ and δ isoforms, respectively, suggesting that, under these experimental 270 
conditions, p38α,  p38β and p38δ were able to phosphorylate at least two sites on 271 
HSF1. With 0.06 mU/μl of enzyme and 15 min incubation, the stoichiometry of the 272 
reaction for HSF1 was 0.04, 0.03, 0.03, and 0.28 mol/mol for p38α,  p38β,  p38γ and  273 
p38δ, respectively (Fig. 6B, black bars), indicating that p38δ was the most efficient 274 
catalyst among the isoforms. The p38δ-mediated phosphorylation of HSF1 was 275 
inhibited by BIRB0796 (Fig. 6E), which inhibits all p38 MAPK isoforms (41). In 276 
contrast to wild-type (WT) HSF1, under the same experimental conditions, the 277 
stoichiometry of the reaction for mutant HSF1, in which S326 was replaced with 278 
alanine (S326A) was 0.02, 0.02, 0.01 and 0.14 mol/mol for the p38α, β, γ and δ 279 
isoforms, respectively (Fig. 6B, grey bars and Fig. 6C), implicating S326 as one of 280 
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the phosphorylation sites, and confirming the existence of additional site(s) on HSF1 281 
which are also phosphorylated by p38 MAPK. Interestingly, this experiment also 282 
showed that, although not as robust as p38δ, p38γ was the most selective isoform in 283 
phosphorylating S326. 284 
To confirm the unusually high substrate preference of p38δ for HSF1 relative 285 
to the more widely studied p38α/β isoforms, we carried out analogous reactions with 286 
MK2 as a substrate. In comparison with p38δ, the initial rates of activation of this 287 
physiological substrate are ~20 times faster for the α or β isoforms (44). Indeed, p38δ 288 
was far less effective in phosphorylating MK2 than was p38α (Fig. 6F). In sharp 289 
contrast, p38δ was more than 20-fold more efficient than p38α in catalyzing the 290 
phosphorylation of HSF1. As expected, the p38α−, but not p38δ−mediated 291 
phosphorylation of all three substrates was dose-dependently inhibited by the p38α/β 292 
inhibitor SB202190.  293 
As mentioned above, we employed MBP-MKK6 to obtain active bacterially 294 
produced human p38 MAPK. To make absolutely certain that the phosphorylation of 295 
HSF1 was not due to any residual MKK6, a new preparation of p38δ was made in 296 
parallela preparation of a kinase-dead mutant (D168A) version of the 297 
enzyme under identical conditions. After incubation and removal of the activating 298 
kinase, each protein was used at an equivalent concentration in a reaction with HSF1 299 
as a substrate. Phosphorylation of HSF1 only occurred with the active, but not kinase-300 
dead p38δ, as revealed by autoradiography and western blot analysis (Fig. 6G), 301 
establishing the p38δ enzyme as the only HSF1 kinase activity in the preparation. 302 
Together, these data demonstrate that HSF1 can be phosphorylated in vitro by 303 
all p38 MAPK isoforms at S326, and that p38δ is the most efficient catalyst among 304 
the isoforms, whereas p38γ is the most specific. However, it is important to note that 305 
S326 is not the only site of phosphorylation by these kinases as the S326A mutant 306 
HSF1 was also phosphorylated, albeit with the expected reduction in stoichiometry. 307 
To identify the phosphorylation sites precisely, we employed a protease-mass 308 
spectrometric approach. Recombinant HSF1 was incubated with recombinant p38α or 309 
p38δ and, after electrophoretic separation and in-gel proteolytic digestion, the 310 
resulting tryptic peptides were analyzed by mass spectrometry. Under these 311 
conditions, the sequence coverage was ~50%. We found that the two p38 isoforms 312 
phosphorylated identical sites (Table 1), suggesting that the increased phosphate 313 
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incorporation with p38δ  due to a faster rate of phosphorylation of the same sites 314 
that were phosphorylated by p38α and not due to phosphorylation of additional site(s). 315 
Three phosphorylated peptides were identified in each sample. The corresponding 316 
mass (m/z 2902.4659 for p38α and m/z 2902.4683 for p38δ) of the longest peptide 317 
was in precise agreement with the calculated molecular weight of a peptide containing 318 
phosphorylated S326 (m/z 2902.4689, 319 
R.VEEASPGRPSSVDTLLS326PTALIDSILR.E). The mass of the shorter peptides 320 
(m/z 1299.5487 and 1526.7121 for p38α and m/z 1299.5493 and 1526.7121 for p38δ) 321 
corresponded exactly to the molecular weight of peptides K.EEPPSPPQS307PR.V 322 
(m/z 1299.5496) and R.VKEEPPS303PPQS307PR.V (m/z 1526.7130), in which both 323 
S303 and S307 were phosphorylated. Notably, S303 was found in both 324 
phosphorylated as well as unphosphorylated forms. The phosphorylation of HSF1 at 325 
S303/307 by the same kinase which phosphorylates the transcription factor at S326 326 
was at first glance surprising, because in contrast to the activating S326 327 
phosphorylation, phosphorylation at S303/307 is inhibitory (14-16). However, this 328 
finding provides a possible explanation for the observation that although PEITC 329 
treatment causes a concentration-dependent increase in HSF1 phosphorylation (Fig. 3 330 
and 4A), induction of Hsp70 is lower at the higher PEITC concentration (Fig. 1B, 3A 331 
and 4A). Immunoblotting with isoform-specific antibodies showed that p38α, p38γ 332 
and p38δ are well expressed in MDA-MB-231 cells, and confirmed that the levels of 333 
these kinases did not change upon exposure to PEITC (Fig. 4E).  334 
 335 
Deletion or inhibition of p38γ decreases the phosphorylation of HSF1 at S326 in 336 
cells. To address whether p38γ and p38δ play a role in the phosphorylation of HSF1 337 
at S326 in cells, we first used the human epidermoid cancer cell line A431, in which 338 
both p38γ and p38δ are expressed, along with its derivatives in which p38γ or p38δ 339 
had been stably knocked down by more than 90%, using selective short hairpin RNA 340 
(shRNA) (Fig. 7A) (45). In comparison to the parental cells or cells deficient in p38δ, 341 
the heat shock-mediated phosphorylation of HSF1 at S326 was reduced by 60% in 342 
cells lacking p38γ (Fig. 7B), in close agreement with the high selectivity of this 343 
isoform for the S326 phosphorylation in vitro (Fig. 6B-D). Treatment with the 344 
p38α/β-specific inhibitor SB202190 had no further effect, indicating that p38α and 345 
p38β do not contribute significantly to the phosphorylation of S326 in these cells (Fig. 346 
7B).  347 
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Similar results were obtained in MDA-MB-231 cells: shRNA-mediated 348 
knockdown (by more than 90%) of p38γ led to a substantial reduction (by ~50%) in 349 
the phosphorylation of HSF1 at S326 at basal cell culture conditions, whereas the 350 
knockdown of p38δ did not have this effect (Fig. 7C). The knockdown of p38γ led a 351 
corresponding decrease in the levels of Hsp70 (Fig. 7C). Interestingly, the levels of 352 
Hsp70 were also reduced upon p38δ knockdown, even though the phosphorylation of 353 
HSF1 at S326 was not affected. These data suggest that p38δ might be involved in 354 
catalyzing the phosphorylation of other (than S326) sites, which activate HSF1, 355 
consistent with the highest stoichiometry of the reaction of this p38 isoform in vitro 356 
with both WT and S326A mutant HSF1 (Fig. 6B,C); the identity of these potential 357 
sites is presently unknown.  358 
The conclusion that p38α and p38β do not contribute significantly to the 359 
phosphorylation of S326 in A431 cells was further supported by studies in PEITC-360 
treated MDA-MB-231 cells, where SB202190 either had no effect (at the high 361 
concentration of PEITC) or even enhanced by 2.5-fold (at the low concentration of 362 
PEITC) the levels of pS326 HSF1 after exposure to the isothiocyanate (Fig. 6D). The 363 
activation of p38α/β by PEITC and the efficacy of SB202190 were confirmed by 364 
monitoring the levels of phosphorylated (at T334) MK2 (Fig. 7D). Finally, we used 365 
BIRB0796, which inhibits all four p38 MAPK isoforms (41). Pre-treatment with 366 
BIRB0796 for 1 h reduced the phosphorylation of S326 in PEITC-treated MDA-MB-367 
231 cells (Fig. 7E). Together, these findings strongly suggest that p38γ is the 368 
principal p38 MAPK isoform responsible for the phosphorylation of HSF1 at S326 in 369 
cells. 370 
Phosphorylation at S326, but not at any of the other serine residues identified 371 
by Guettouche et al., has been shown to affect the heat shock-induced transcriptional 372 
activity of HSF1 without affecting the trimerization of nuclear translocation of the 373 
transcription factor. In agreement, we found that both purified recombinant wild-type 374 
and S326A mutant HSF1 have the propensity to form dimers and trimers 375 
spontaneously (Fig. 6A). By use of quantitative high content imaging, we examined 376 
the nuclear and cytoplasmic distribution of wild-type, S326A or S326E mutant GFP-377 
HSF1 fusion proteins after their ectopic expression in HSF1-knockout MEFs, and did 378 
not observe any significant differences among the genotypes (Fig. 8). Notably 379 
however, these results should be interpreted with caution: it is well documented that 380 
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in C. elegans, ectopic expression of HSF1 produces a gain-of-function phenotype (46, 381 
47), indicating that any level of overexpression of HSF1 may not accurately reflect 382 
the physiological properties of the endogenous protein.  383 
 384 
Discussion 385 
By use of mass spectrometry and protein sequencing, Guettouche et al. (19) found 386 
that in cells subjected to heat shock, human HSF1 is phosphorylated at 12 serine 387 
residues: S121, S230, S292, S303, S307, S314, S319, S326, S344, S363, S419, and 388 
S444. More recently, using mass spectrometry-based proteomics, Xu et al. (48) 389 
reported the phosphorylation at five additional serine residues (S127, S195, S216, 390 
S320, and S368), and at four threonine residues (T142, T323, T367, and T369). The 391 
functional significance of most threonine phosphorylations is unknown, except for 392 
T142, the phosphorylation of which by casein kinase 2 (CK2) has been reported to 393 
increase the transcriptional activity of HSF1 (49). It is well established that 394 
phosphorylations at S303/307, S121 and S363 inhibit the function of the transcription 395 
factor and are involved in the attenuation phase of the heat shock response (14-16, 18), 396 
whereas phosphorylation at S216 by Polo-like kinase 1 (PLK1) promotes the 397 
ubiquitination and degradation of HSF1 during mitosis (50). Curiously, PLK1 also 398 
phosphorylates HSF1 at S419, but in contrast to the inhibitory S216 phosphorylation, 399 
phosphorylation at S419 is activating and promotes the nuclear translocation of the 400 
transcription factor (51). Phosphorylation at S320 by protein kinase A (PKA) also 401 
activates HSF1 (52). Another activating phosphorylation occurs at S230; it is 402 
catalysed by calcium/calmodulin-dependent protein kinase II (CaMKII) and enhances 403 
the magnitude of the response upon heat stress (53). Although the DNA-binding 404 
ability of the S230A mutant of HSF is retained, its transcriptional activity is reduced 405 
by ~50% in comparison with wild-type HSF1.  406 
Phosphorylation at S326 is a hallmark for HSF1 activation, and several studies 407 
have attempted to identify the kinase(s) phosphorylating this site. It was reported that 408 
the mechanistic target of rapamycin (mTOR) is able to catalyze the phosphorylation 409 
of HSF1 at S326 (20). However, PEITC inhibits mTOR (54). In full agreement, we 410 
also found that the mTOR pathway was inhibited by PEITC, as evidenced by the 411 
decreased phosphorylation of the ribosomal subunit S6 at S235/236 (Fig. 4B). Overall, 412 
our data presented in this contribution imply that mTOR is not the primary kinase 413 
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responsible for the phosphorylation of S326 on HSF1 in response to treatment with 414 
PEITC, and further implicate the family of proline-directed p38 MAPK as highly 415 
efficient catalysts, which phosphorylate HSF1 rapidly and stoichiometrically. Notably 416 
however, neither pharmacological inhibition of p38 MAPK by small molecule 417 
inhibitors or genetic downregulation of p38γ or p38δ eliminated completely the 418 
phosphorylation of HSF1 at S326 (Fig. 7). These results imply that although p38γ is 419 
the principal isoform within the p38 MAPK family that phosphorylates this site, 420 
inactivation of p38γ allows for compensation by other kinases. One such candidate is 421 
JNK1/2, which is also activated by PEITC, albeit at a later time point in comparison 422 
with p38 MAPK (Fig. 4D). It has been reported that p38 MAPK engage in feedback 423 
control loops that suppress the activities of upstream MAP kinase kinase kinases 424 
(MAP3Ks), which participate in the activation JNK, and by disrupting these feedback 425 
control loops, inhibition of p38 leads to hyperactivation of JNK (55). The possibility 426 
that JNK1/2 could phosphorylate HSF1 at S326 requires a further study. 427 
Interestingly and unexpectedly, we found that in addition to S326, p38 MAPK 428 
can also catalyze the phosphorylation of HSF1 at S303/307. In contrast to the 429 
activating function of the S326 phosphorylation, phosphorylation at S303/307 inhibits 430 
the function of HSF1 (14-16). Although surprising, the fact that the same kinase can 431 
catalyze phosphorylation of two distinct sites on HSF1 with opposing functional 432 
consequences is not unprecedented. As mentioned above, phosphorylation at S216 by 433 
PLK1 inhibits HSF1, whereas phosphorylation at S419 by the same kinase activates 434 
the transcription factor (50, 51). Our results imply that either p38 MAPK 435 
phosphorylate S326 at a faster rate than at S303/307, thus giving a “window” of HSF1 436 
activation due to S326 phosphorylation before the repressive effect of S303/307 437 
phosphorylation takes place, or alternatively, that there is a threshold of MAPK p38 438 
activation below which S326 is the principal target, and above which the S303/307 439 
phosphorylation becomes dominant. The second possibility is supported by the fact 440 
that induction of Hsp70 is lower upon treatment with the higher (20 μM) compared to 441 
the lower (10 μM) concentration of PEITC, whereas the extent of HSF1 442 
phosphorylation is dependent on the dose of PEITC. In addition, the identity of the 443 
phosphatases involved may also influence the relative turnover rates of 444 
phosphorylation at each site. Dissecting these possibilities requires better tools for 445 
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quantitation of relative stoichiometry of phosphorylation at S303/307 vs. S326 in 446 
different cell compartments.  447 
Previous investigations have suggested the possible involvement of MAPK 448 
signaling in the activation of HSF1. Thus, loss of the tumor suppressor 449 
neurofibromatosis type 1 (NF1) leads to activation of MAPK signaling and HSF1 (6). 450 
Chronic exposure of rodent fibroblast cells to heat stress causes phosphorylation of 451 
p38 MAPK and induction of Hsp70 (56, 57). In addition, the anti-inflammatory agent 452 
sodium salicylate, has been reported to activate p38 MAPK, promote HSF1 DNA 453 
binding and transcriptional activity, and induce Hsp70 expression (58). Most recently, 454 
it was reported that HSF1 physically interacts and is phosphorylated by MEK (42). 455 
However, to our knowledge, there are no prior publications linking HSF1 456 
phosphorylation at S326 directly with p38 MAPK activation. In our study, the 457 
identification of p38 MAPK as one family of kinases, which phosphorylate HSF1 at 458 
S326 was greatly facilitated by the observation that PEITC is an exceptionally robust 459 
activator of HSE-dependent transcription (Fig. 1F). PEITC shares the ability to 460 
induce the heat shock response with celastrol (59, 60), another natural product which 461 
like PEITC, has a characteristic chemical signature, reactivity with sulfhydryl groups 462 
(61). Notably, in a screen comprising ~900 000 small molecules, Calamini et al. (34) 463 
discovered new classes of HSF1 activators, all of which, although structurally diverse, 464 
bear the same chemical signature. We propose that this chemical property underlies 465 
the ability of PEITC to both inhibit Hsp90 as well as activate p38 MAPK. Finally, 466 
pharmacological targeting of p38γ and p38δ has been recently proposed for the 467 
treatment of autoimmune and inflammatory diseases, as well as cancer (62). As HSF1 468 
activation supports malignant transformation (5), this approach holds promise for 469 
targeting HSF1 for cancer treatment. 470 
 471 
Materials and Methods 472 
Materials.  All general chemicals and reagents were of analytical grade and obtained 473 
from Sigma-Aldrich (Dorset, United Kingdom). PEITC was prepared as a stock 474 
solution in acetonitrile and diluted 1:1,000 in the cell culture medium before treatment. 475 
The concentration of the solvent was maintained at 0.1% (v/v) in all wells. The 476 
p38α/β MAPK inhibitor SB202190 was purchased from SYNkinase. The JNK 477 
inhibitor JNK-In-8 was a kind gift from Dario Alessi (University of Dundee). 478 
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 479 
Cell culture.  MDA-MB-231 cells were from ATCC. HeLa-HSE-luc cells (34) were 480 
a generous gift from Richard I. Morimoto (Northwestern University, USA). Mouse 481 
embryonic fibroblasts (MEF) from wild-type or HSF1-knockout mice were isolated as 482 
described previously (63). The human epidermoid cancer cell line A431 and the 483 
production and transduction of lentivirus short hairpin RNA to generate stable clones, 484 
which do not express p38γ or p38δ, have been described (45). All cell lines were 485 
maintained at 5% CO2 in air at 37°C and were cultured in Dulbecco's Modified Eagle 486 
Medium (DMEM) supplemented with 10% (v/v) heat-inactivated FBS. The medium 487 
in which HeLa-HSE-luc cells were grown also contained 100 µg/mL G418 488 
(Invitrogen), whereas the medium for MEF cells was additionally supplemented with 489 
non-essential amino acids and 50 U/ml penicillin/streptomycin. 490 
 491 
Western blotting.  Cells grown in 6-well plates were washed twice with phosphate 492 
buffered saline (PBS) and lysed in 150 μl of either RIPA buffer [50 mM Tris-Cl pH 493 
7.5, 150 mM NaCl, 0.5% (w/v) sodium deoxycholate, 1% NP-40 (v/v), 0.1% SDS 494 
(w/v) and 1 mM EDTA), containing 1 protease inhibitor cocktail tablet (Roche) per 495 
10 ml of buffer] or SDS lysis buffer [50 mM Tris-Cl pH 6.8, 2% (w/v) SDS, 10% 496 
(v/v) glycerol and 0.005% bromophenol blue). The lysates derived from RIPA buffer 497 
were transferred into 1.5-ml Eppendorf tubes which were placed on a rotator at 4°C 498 
for 30 min. The cell debris was then removed by centrifugation at 16,300 x g for 10 499 
min at 4°C, and the supernatant was transferred to a new tube. The lysates derived 500 
from the SDS lysis buffer were subjected to sonication at 20% amplitude for 20 sec. 501 
The BCA assay (Thermo) was used to determine protein concentrations. Proteins 502 
were resolved by SDS/PAGE, transferred to immobilon-P membranes, and probed 503 
with specific antibodies against Hsp70 (mouse monoclonal, 1:1,000, StressMarq, 504 
York, United Kingdom), Hsp90 (mouse monoclonal, 1: 5,000, BD Biosciences, New 505 
Jersey, USA), HER2 (rabbit polyclonal, 1:500, Millipore, California, USA), RAF1 506 
(rabbit polyclonal, 1:200, Santa Cruz, California, USA), HSF1 (rabbit polyclonal, 507 
1:1,000, Enzo Life Sciences, Exeter, United Kingdom), pS326-HSF1 (rabbit 508 
polyclonal, 1:10,000, Abcam, Cambridge, United Kingdom), p38 MAPK (rabbit 509 
polyclonal, 1:1,000, Cell Signaling, Massachusetts, USA), pp38 MAPK (rabbit 510 
polyclonal, 1:1,000, Cell Signaling, Massachusetts, USA), JNK1/2 (rabbit polyclonal, 511 
1:1,000, Cell Signaling, Massachusetts, USA), pJNK1/2 (rabbit polyclonal, 1:1,000, 512 
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Biosource Europe, Nivelles, Belgium), pERK1/2 (rabbit polyclonal, 1:1,000, Cell 513 
Signaling, Massachusetts, USA), pT334-MK2 (rabbit polyclonal, 1:1,000, Cell 514 
Signaling, Massachusetts, USA), and pS235/6 S6 (rabbit polyclonal, 1:5,000, Cell 515 
Signaling, Massachusetts, USA). Isoform-specific p38γ and p38δ MAPK antibodies 516 
were from the Division of Signal Transduction Therapy (DSTT), and were used at a 517 
concentration of 1 μg/ml. Equal loading was confirmed by probing the blots with 518 
antibodies against GAPDH (rabbit polyclonal, 1:5,000) or β-actin (mouse monoclonal, 519 
1:10,000), both from Sigma, Dorset, United Kingdom, or Lamin A (rabbit polyclonal, 520 
1:1,000, GeneTex, Irvine, CA, USA). The western blots shown are representative of 521 
at least three independent experiments. 522 
 523 
Nuclear-cytoplasmic separation.  MDA-MB-231 cells (106 per dish) were plated in 524 
6-cm dishes and treated for the indicated periods of time with 0.1% (v/v) acetonitrile 525 
or PEITC. The REAP method described by Suzuki et al. (64) was used to obtain 526 
separate cytoplasmic and nuclear fractions. In short, cells were washed twice with ice-527 
cold phosphate buffered saline (PBS, pH 7.5), collected in 500 μl of ice-cold PBS, 528 
transferred to Eppendorf tubes, and subjected to centrifugation at 10,000 x g for 30 529 
sec at room temperature. Next, the supernatant was discarded and the pellet was 530 
resuspended in 450 μl of ice-cold 0.1% NP-40 (v/v) in PBS. The lysates were then 531 
subjected to a further centrifugation at 10,000 x g for 30 sec at room temperature. The 532 
supernatant was collected as the cytoplasmic fraction. One volume of 5X sample SDS 533 
loading buffer [250 mM Tris-Cl pH 6.8, 10% (v/v) sodium dodecyl sulphate, 50% 534 
(v/v) glycerol and 0.025% (w/v) bromophenol blue] was added to four volumes of the 535 
cytoplasmic fraction and the samples were heated for 5 min at 100oC and subjected to 536 
SDS/PAGE. The remaining pellet containing the nuclear fraction was washed twice 537 
with ice cold 0.1% NP-40 (v/v) in PBS and dissolved in 1X sample loading buffer [50 538 
mM Tris-Cl pH 6.8, 2% (v/v) sodium dodecyl sulphate, 10% (v/v) glycerol and 539 
0.005% (w/v) bromophenol blue] and heated for 5 min at 100oC. The nuclear 540 
fractions were sonicated before subjecting them to SDS-PAGE. 541 
 542 
Quantitative real-time PCR.  The primers and probes for quantifying the levels of 543 
the mRNA species were from Applied Biosystems (hspa1a: Mm01159846_s1; HER2: 544 
HS01001580_m1 and RAF1: HS00234119_m1). Cells (2 x 105 per well) were seeded 545 
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in 6-well plates. After 24 h, the cells were exposed to vehicle (0.1% acetonitrile) or 546 
PEITC for a further 8 (MEFs) or 16 h (MEFs and MDA-MB-231 cells).  After cell 547 
lysis, total RNA was extracted using RNeasy Kit (Qiagen Ltd.), and 500 ng total RNA 548 
was reverse transcribed into cDNA with Omniscript Reverse Transcription Kit 549 
(Qiagen Ltd.). Real-time PCR was performed on Applied Biosystems 7900HT Fast 550 
Real-Time PCR System. The data were normalized using β-actin (mouse ACTB, 551 
Applied Biosystems, Mm00607939_s1) as an internal control. 552 
 553 
Luciferase assay. HeLa-HSE-luc cells (105 per well) were seeded in each well of a 554 
24-well plate, and 24 h later treated with PEITC or 0.1% (v/v) acetonitrile vehicle for 555 
8-, 16-, 24-, or 48 h. Cells were washed twice with 0.1% PBS, and 100 µl of 1X 556 
reporter lysis buffer (Promega) was added to each well. The plate was placed at -20°C 557 
for a minimum for 2 h, and then transferred to thaw on a shaker at room temperature 558 
for 30 min. Cell lysates were collected into Eppendorf tubes and subjected to 559 
centrifugation at 15,000 x g for 2 min at 4°C. Luciferase activity was measured in 10 560 
µl of cell lysate in opaque 96-well plates (Corning) using a microplate-reader based 561 
luminometer (Orion II, Berthold), and normalized for protein concentration 562 
determined by the Bradford’s assay (BioRad). 563 
 564 
ATP-binding assay. MDA-MB-231 cells (0.5 x 106 per dish) were seeded in 6-cm 565 
dishes. After 24 h, the cells were treated for a further 24 h with 0.1% acetonitrile as 566 
the vehicle control for sulfoxythiocarbamate alkyne (STCA, 75 µM) and PEITC (20 567 
µM) treatments, or with 0.1% DMSO as the vehicle control for the geldanamycin 568 
(GA, 1 µM) and celastrol (CL, 0.8 µM) treatments. Cells were harvested by scraping 569 
into 300 µl of lysis buffer [10 mM Tris pH 7.5, 150 mM NaCl, 0.25% NP40, with one 570 
protease inhibitor tablet (Roche) per 10.0 ml of buffer], frozen, thawed, and lysed for 571 
30 min at 4°C. ATP-agarose beads (Jena Bioscience) were washed with the 572 
incubation buffer (10 mM Tris pH 7.5, 150 mM NaCl, 20 mM MgCl2, 0.05% NP40, 1 573 
mM DTT). Cell lysates (200 µg total protein) were added to a suspension of 30 µl of 574 
beads in 1.25 ml of buffer, and the samples were incubated rotating overnight at 4°C.  575 
The beads were collected by centrifugation and washed three times with the 576 
incubation buffer. SDS loading buffer (10 µl) and incubation buffer (40 µl) were 577 
added to the beads, and the samples were incubated for 5 min at 100°C. The beads 578 
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were pelleted by centrifugation, and the supernatants were collected and subjected to 579 
western blot analysis. 580 
 581 
Detection of HSF1 trimerization. MDA-MB-231 (2 x 106 per dish) cells were grown 582 
on 10-cm dishes for 24 h and treated with 0.1% acetonitrile or 20 μM PEITC for a 583 
further 3 h. Cells were then washed twice with PBS. 10 ml of 0.4% paraformaldehyde 584 
(w/v) in PBS (0.4% PFA-PBS) was added to the dishes over 10 min, where fresh 585 
0.4% PFA-PBS was added every 5 min. Next, the PFA-PBS was removed and the 586 
reaction was quenched with the addition of 3 ml of ice-cold 1.25 M Glycine-PBS. 587 
After washing twice with PBS, nuclear and cytoplasmic fractions were obtained. Cells 588 
were lysed in buffer A [10 mM KCl, 5 mM MgCl2, 50 mM Tris-Cl pH 7.5, 0.5% (v/v) 589 
NP-40, 1 mM DTT, one EDTA-free complete mini protease inhibitor cocktail tablet 590 
(Roche) and one phos-STOP tablet (Roche) per 10 ml of buffer]. The lysates were 591 
subjected to centrifugation at 1,000 x g for 5 min at 4oC. The supernatant containing 592 
the cytoplasmic fraction was transferred to a fresh Eppendorf tube where one volume 593 
of 5X SDS sample loading buffer was added to four volumes of the cytoplasmic 594 
fraction. The pellet containing the nuclear fraction was washed there times with the 595 
buffer A before dissolving it in 1X sample loading buffer [50 mM Tris-Cl pH 7.4, 2% 596 
(w/v) SDS, 10% (v/v) glycerol, and 0.005% (w/v) bromophenol blue]. The nuclear 597 
fractions were subjected to sonication. Both the cytoplasmic and the nuclear fractions 598 
were subjected to SDS-PAGE before immunoblotting. 599 
 600 
Co-immunoprecipitation. MDA-MB-231 (4 x 106 per dish) cells were grown on 10-601 
cm dishes for 24 h, and the treated with 0.1% DMSO or 20 μM PEITC for 45 min. 602 
The dishes with cells were placed on ice and washed twice with ice-cold PBS. Protein 603 
G Dynabeads (30 μl slurry, from Invitrogen) were washed twice for 5 min with PBS 604 
and incubated with 1 μg of mouse monoclonal HSF1 antibody (Santa Cruz) for 1 h at 605 
room temperature, after which the beads were washed three times every 10 min with 606 
PBS. Cells were lysed with 1.0 ml ice-cold CO-IP buffer (150 mM NaCl, 50 mM 607 
Tris-Cl, pH 7.4, 1 mM EDTA, 1% NP-40, 0.1% w/v sodium deoxycholate) 608 
supplemented with one EDTA-free protease cocktail inhibitor tablet (Roche) and one 609 
phosphatase inhibitor tablet (PhoSTOP Roche). Cell lysates were passed through a 610 
23-gauge needle 10 times before they were clarified by centrifugation at 4°C for 30 611 
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min at 16,000 x g. Fifty μl of the clarified lysate (IP sample) was transferred to a fresh 612 
Eppendorf tube to serve as an input sample. To pre-clear the IP sample, 30 μl of 613 
Protein G Dynabeads slurry was washed twice for 5 min with PBS, and the beads 614 
were added to each of the IP sample (containing 0.8-1.0 mg protein), and incubated 615 
for 1 h at 4°C on a tube rotator. Subsequently, the Protein G Dynabead-antibody 616 
conjugate was added to the pre-cleared IP sample and incubated for 16 h at 4°C on a 617 
tube rotator. The immunoprecipitated complexes were washed three times with ice-618 
cold CO-IP buffer every 10 min, and were eluted from the beads by adding 70 μl of 619 
1X LDS buffer (Invitrogen) and heating the sample at 70°C for 10 min. After cooling, 620 
7 μl of sample reducing agent (SRA, Invitrogen) was added to the sample, and 621 
incubated for 15 min at room temperature. Immuproprecipitated proteins (35 μl) were 622 
resolved by electrophoresis. Antibodies against Hsp90 (monoclonal, BD Biosciences) 623 
and HSF1 (rabbit polyclonal, Enzo Life Sciences) were used for detection of the 624 
respective proteins. 625 
 626 
Generation of p38γ and p38δ stable knockdown cell lines. p38γ and p38δ 627 
expression was reduced by RNA interference using Mission shRNA constructs 628 
(Sigma; plasmid clone IDs TRCN0000006145 and TRCN0000006147 for p38γ, and 629 
TRCN0000000827 and TRCN0000009979 for p38δ). A lentivirus containing the 630 
control pLKO.1 or the shRNA plasmids was used to infect MDA-MB-231 cells. To 631 
produce the virus, HEK293T cells were transfected using Lipofectamine 2000 632 
(Invitrogen) with empty pLKO.1-puro vector or the shRNA constructs against p38γ or 633 
p38δ, together with the packaging vectors (psPAX2 and pMD2.G) in serum-reduced 634 
medium. On the following day, the medium was replaced with complete DMEM, and 635 
after 24 h, the lentivirus-containing supernatant was collected, filtered, and used to 636 
transduce MDA-MB-231 cells. Cells containing the shRNA plasmid were selected, 637 
expanded and maintained with supplementation of puromycin (2 mg/ml) for 638 
approximately three weeks, during which time cell lysates were collected every three 639 
to four days to ensure the respective p38 expression levels were reduced throughout 640 
the selection period. 641 
 642 
Expression and purification of recombinant hexahistidine-tagged HSF1. Full-643 
length HSF1 cDNA was amplified by PCR from a plasmid obtained from Addgene 644 
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(Plasmid ID: #32537, in which the cDNA sequence was found to have a nucleotide 645 
substitution at position 1343 from a C to T, leading to a change from P to L at 646 
position 448 in the protein sequence) and subcloned into the bacterial expression 647 
vector pet15b using Nde1 and Xho1. Following transformation into E.coli 648 
(BL21(DE3)pLysS), the cells were grown to an optical density at 600 nm of 0.6, and 649 
induced for a further 3.5 h at 37°C with 400 mM isopropyl-β-D-650 
thiogalactopyranoside (IPTG). The induced cells were harvested by centrifugation 651 
and resuspended in extraction buffer [20 mM Tris-Cl pH 7.9, 150 mM NaCl, 5 mM 652 
imidazole and 0.01% (v/v) IGEPAL CA-630]. After freezing and thawing, the cells 653 
were disrupted by sonication for 5 min on ice. Cell debris were then cleared by 654 
centrifugation at 10,000 x g for 15 min at 4oC. The resultant supernatant was left on 655 
ice for 30 min before applying to nickel agarose resin (His-TrapTMHP, GE 656 
Healthcare). The resin was washed with 20 mM Tris-Cl pH 7.9, 150 mM NaCl, 5 mM 657 
imidazole. The supernatant (20 ml) was then incubated for 1 h at 4°C with 1 ml resin. 658 
After three washes with buffer, the protein was eluted with 2 ml of 20 mM Tris-Cl pH 659 
7.9, 150 mM NaCl, 250 mM imidazole. To remove the imidazole, the preparation was 660 
dialyzed in 50 mM Tris-Cl pH 7.4, 150 mM NaCl. Mutant S326A HSF1 was 661 
generated by site-directed mutagenesis of the plasmid vector pet15b containing the 662 
HSF1 cDNA by using the primers 5’-663 
GTGGACACCCTCTTGGCCCCGACCGCCCTCATTG-3’and 664 
5’CAATGAGGGCGGTCGGGGCCAAGAGGGTGTCCAC-3’ and the 665 
QuikChange® II Mutagenesis kit (Stratagene). The hexahistidine-tagged mutant 666 
S326A HSF1 recombinant protein was generated using the method described above. 667 
 668 
High content microscopy and analysis.  HSF1-knockout MEFs were seeded in 669 
black-walled 96-well plates (Corning Costar 3904) at 4 x 103 cells/well and 670 
transfected with 50ng/well GFP-tagged wild-type or S326A or S326E mutants of 671 
HSF1 using Lipofectamine LTX reagent (Invitrogen), using 8 replicate wells per 672 
condition. Twenty-four hours after transfection, cells were fixed using 4% 673 
paraformaldehyde in PBS for 10 min at room temperature, and permeabilised using 674 
methanol at -20°C for 5 min. Cells were blocked using 2.5% normal goat serum in 675 
PBS/0.1% sodium azide, and counterstained using rabbit anti-ERK1/2 mAb (clone 676 
137F5, Cell Signaling Technology) and Alexa 546 labelled highly cross adsorbed 677 
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goat anti-rabbit secondary antibody (Invitrogen). DNA was labelled with 300 nM 678 
DAPI (Sigma) in PBS and images were acquired using an IN Cell Analyzer 2000 679 
robotic fluorescence microscope (GE Healthcare) using a 20x lens to capture 4 fields 680 
per well for each fluorophore (DAPI, GFP and Alexa 546) using 2x2 pixel binning to 681 
maximise signal/noise. Images were analyzed using a custom algorithm constructed 682 
within IN Cell Developer software (GE Healthcare), using DAPI and ERK1/2 images 683 
to identify nuclear and cytoplasmic regions, respectively, in order to assess 684 
fluorescence distribution within the GFP channel. 685 
 686 
Kinase assays. The incubation mixtures contained purified recombinant kinase (at a 687 
specific activity of either 6 mU/μl or 0.06 mU/μl), recombinant HSF1 (1 μg) substrate, 688 
10 mM MgCl2, 0.1 mM [γ-32P]-ATP (approximately 0.5 x 106 cpm/nmol), and kinase 689 
buffer [50 mM Tris-Cl, 0.03% (v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol] in a total 690 
volume of 50 μl. The kinase assays were performed at 30°C. At the times indicated, a 691 
15-μl aliquot of each incubation mixture was removed, the reaction was terminated by 692 
the addition of SDS gel loading buffer, the sample was loaded on SDS-PAGE, and the 693 
excess [γ-32P]-ATP was removed by electrophoresis. The gels were dried and 694 
subjected to autoradiography. Protein-containing gel pieces (visualized by staining 695 
with Coomassie Brilliant Blue) were then excised, and phosphate incorporation into 696 
HSF1 was quantified by scintillation counting. 697 
Cold assays were performed in an analogous manner using purified 698 
recombinant kinase (at a specific activity of 0.06 mU/μl), recombinant HSF1 (1 μg) 699 
substrate, MgCl2 (10 mM), and ATP (0.1 mM) instead of [γ-32P]-ATP. For 700 
identification of the phosphorylated sites, the gel bands were excised, reduced with 701 
DTT (10 mM), alkylated with iodoacetamide (50 mM), and digested overnight (16 h) 702 
with trypsin (Modified Sequencing Grade, Roche) at 30°C. The resulting peptides 703 
were extracted from the gel, dried in a SpeedVac concentrator (Thermo Scientific), 704 
resuspended in 10 µl 5% formic acid, and diluted five times. Any residual particles 705 
were removed by centrifugation, the samples were then transferred to HPLC vials, 706 
and analyzed by LC/MS/MS on Ultimate3000 RSLCnano System (Thermo Scientific) 707 
coupled to a LTQ OrbiTrap VelosPro (Thermo Scientific) with EasySpray source. 708 
The data files were analyzed with Proteome Discoverer (Ver. 1.4.1) using Mascot 709 
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(Ver. 2.4.1) as the search engine using Protein specific database (HisTag-HSF1) and 710 
IPI-Human (ipi.HUMAN.v3.87) database. 711 
 712 
Statistical analysis.  Values are means ± 1 SD. The differences between groups were 713 
determined by Student’s t-test. Analyses were performed using Excel (Microsoft 714 
Corp.). 715 
 716 
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Figure Legends 727 
Figure 1.  PEITC is a robust inducer of the heat shock response.  (A) Chemical 728 
structures of allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), and 729 
phenethyl isothiocyanate (PEITC). (B, C) MDA-MB-231 cells (2.5 x 105 per well) 730 
(B) or mouse embryonic fibroblasts (MEF, 2 x 105 per well) (C) growing in 6-well 731 
plates were exposed to vehicle (0.1% acetonitrile), AITC, BITC, or PEITC for 16 h. 732 
Cells were lysed in RIPA buffer, proteins were resolved by SDS/PAGE, transferred to 733 
immobilon-P membranes, and probed with an antibody against Hsp70. The levels of 734 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading control. (D) 735 
Wild-type MEF cells (2 x 105 per well) in 6-well plates were exposed to vehicle 736 
(0.1% acetonitrile) or PEITC for 8 or 16 h. Cells were lysed, total RNA was extracted, 737 
and reverse transcribed into cDNA. The mRNA levels for hspa1a were quantified 738 
using real-time PCR. The data were normalized using β-actin as an internal control. 739 
(E) MDA-MB-231 cells (2.5 x 105 per well) growing in 6-well plates were exposed to 740 
vehicle (0.1% acetonitrile) or 20 μM PEITC for 3 h. Cells were then fixed with 0.8% 741 
(v/v) paraformaldehyde. Cell lysates were subjected to nuclear (N) and cytoplasmic 742 
(C) separation, proteins were resolved by SDS/PAGE (10% gel), transferred to 743 
immobilon-P membranes, and probed with an antibody against HSF1. The levels of 744 
lamin B2 and GAPDH served as fraction purity indicators and as loading controls. (F) 745 
HeLa-HSE-luc cells (1.3 x 105 per well) stably transfected with the luciferase gene 746 
under the control of the HSP70.1 promoter, were grown in 12-well plates and exposed 747 
to vehicle (0.1% acetonitrile) or PEITC. Luciferase activity was determined in cell 748 
lysates. The relative luminescence units (RLU) were quantified and normalized with 749 
respect to the vehicle control treatment. Data represent means ± SD and are expressed 750 
as ratio of the relative transcripts in treated over control samples. 751 
 752 
Figure 2.  PEITC inhibits Hsp90. (A) MDA-MB-231 cells (2.5 x 105 per well) in 6-753 
well plates were treated with vehicle (0.1% acetonitrile) or PEITC for 24 h. The levels 754 
of HER2 and RAF1 were detected by western blot analysis. The levels of β-actin 755 
served as loading control. (B) MDA-MB-231 cells (0.5 x 106 per dish) were grown in 756 
6-cm dishes. After 24 h, the cells were treated for a further 24 h with 0.1% acetonitrile 757 
(ACN) as the vehicle control for sulfoxythiocarbamate alkyne (STCA) and PEITC 758 
treatments, or with 0.1% DMSO as the vehicle control for the geldanamycin (GA) and 759 
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celastrol (CL) treatments. Cells were lysed and subjected to ATP pulldown using 760 
ATP-agarose beads. For the ATP pull-down and input samples, Hsp90 or GAPDH 761 
were detected by western blot analyses. (C) MDA-MB-231 cells (2.5 x 105 per well) 762 
were grown in 6-well plates and treated with vehicle (0.1% acetonitrile) or PEITC for 763 
45 min. cells were lysed and subjected to immunoprecipitation with an anti-HSF1 764 
antibody, and then immunoblotted with an anti-Hsp90 antibody. An aliquot of total 765 
lysate was subjected to immunoblot analysis with anti-Hsp90 and anti-HSF1 766 
antibodies. 767 
 768 
Figure 3.  PEITC causes phosphorylation of HSF1 at S326. MDA-MB-231 cells 769 
(2.5 x 105 per well) in 6-well plates were treated with vehicle (0.1% acetonitrile) or 770 
PEITC for either 24 h (A) or for the indicated periods of time (B). In (A), the levels of 771 
pS326 HSF1, total HSF1, and Hsp70 were detected by western blot analysis in cell 772 
lysates, and the levels of β-actin served as loading control. In (B), the levels of pS326 773 
HSF1 were detected by western blot analysis in cytoplasm and nucleus following 774 
nuclear-cytoplasmic separation. The levels of lamin A and GAPDH served as fraction 775 
purity indicators and as loading controls. 776 
 777 
Figure 4.  PEITC activates p38 and JNK1/2 MAPK, and inhibits mTOR. MDA-778 
MB-231 cells (2.5 x 105 per well) growing in 6-well plates were treated with vehicle 779 
(0.1% acetonitrile) or PEITC for either 24 h (A, B), 3 h (C, E) or for the indicated 780 
periods of time (D). The levels of HSF1, pS326 HSF1, pS235/6 S6, Hsp70, the p38 781 
isoforms α, γ, and δ,  phosphorylated p38 (pp38), phosphorylated p38α (pp38α), 782 
JNK1/2, and phosphorylated JNK1/2 (JNK1/2), were detected by western blot 783 
analysis. 784 
 785 
Figure 5. The MEK inhibitor U0126 reduces the levels of heat-shock induced 786 
phosphorylation of HSF1 at S326 after a 24-h pre-treatment, but 1-h pre-787 
treatment has no effect. MDA-MB-231 cells (2.5 x 105 per well) in 6-well plates 788 
were pre-treated with U0126 for either 24 h (A) or 1 h (B), and subsequently 789 
subjected to heat shock (HS). The levels of HSF1 and pS326 HSF1 were detected by 790 
western blot analysis. The levels of β-actin served as loading control. 791 
 792 
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Figure 6.  p38 MAPK phosphorylate HSF1 in vitro. (A) Electrophoretic mobility 793 
(NuPAGE NoVex Bis-Tris 4-12% gradient gel) of recombinant hexahistidine-tagged 794 
HSF1 wild-type (WT) and S326A mutant. (B-G) Purified activated recombinant p38 795 
MAPK isoforms (0.06 mU/μl) were incubated with recombinant wild-type (WT), 796 
S326A mutant HSF1, MK2, or myelin basic protein (MBP) (all at 0.1 μg/μl) at 30°C 797 
for 15 min in the presence of 10 mM MgCl2 and 0.1 mM [γ-32P]-ATP. Identical 798 
reactions were carried out in the presence of increasing concentrations of the p38α/β 799 
inhibitor SB202190 or BIRB0796, which inhibits all p38 isoforms. The reactions 800 
were terminated by addition of SDS gel loading buffer, the samples were loaded on 801 
SDS/PAGE, and the excess [γ-32P]-ATP was removed by electrophoresis. The gels 802 
were dried and subjected to autoradiography (C, E-G). After staining with Coomassie 803 
Brilliant Blue, the protein bands were excised and the incorporated radioactivity (B) 804 
was determined by scintillation counting. *, p < 0.05. (D, F) Purified activated 805 
recombinant p38α (0.06 mU/μl) was incubated with recombinant wild-type (WT) or 806 
S326A mutant HSF1 (0.1 μg/μl) at 30°C for 15 min in the presence of 10 mM MgCl2 807 
and 0.1 mM ATP. The reactions were terminated by addition of SDS gel loading 808 
buffer, the samples were loaded on SDS/PAGE, and the phosphorylation of HSF1 at 809 
S326 and the levels of total HSF1 were detected by western blotting.  810 
 811 
Figure 7. Deletion or inhibition of p38γ MAPK reduces the levels of pS326 HSF1 812 
in cells. (A) Immunoblotting for p38 γ and δ in A431 cells, which either express both 813 
p38γ and p38δ (WT), or in which p38γ or p38δ had been stably knocked down using 814 
selective shRNA. (B) A431 cells (5 x 105 per well, WT or p38γ- or p38δ-deficient) 815 
were pre-incubated for 1 h with vehicle (0.1% acetonitrile) or SB202190, and exposed 816 
to heat shock (42 °C) for a further 1 h. (C) p38γ- or p38δ was stably knocked down in 817 
MDA-MB-231 cells using selective shRNA. The levels of total HSF1, HSF1 818 
phosphorylated at S326, total p38, p38γ, and p38δ, and Hsp70 were detected by 819 
western blot analysis. (D, E) MDA-MB-231 cells (5 x 105 per well) grown in 6-well 820 
plates were pre-treated with vehicle (0.1% acetonitrile), SB202190 or BIRB0796 for 1 821 
h, and subsequently either treated with vehicle (0.1% acetonitrile) or PEITC for a 822 
further 1.5 h. HSF1 phosphorylated at S326 (B-E) and MK2 phosphorylated at T334 823 
(D) were detected by western blot analysis. The levels of α-tubulin (A) or β-actin (B-824 
E) served as loading controls. 825 
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 826 
Figure 8. S326A/E mutation does not influence the nucleo-cytoplasmic 827 
distribution of ectopically expressed HSF1-GFP. HSF1-knockout MEFs were 828 
transfected with GFP-tagged wild-type or S326A/E mutants of HSF1 prior to counter 829 
staining with anti-ERK1/2 antibodies and DAPI. Four fields of view per well of eight 830 
replicate wells per condition were imaged using a robotic high content microscope. 831 
Automated and systematic analysis of images was performed using a custom 832 
algorithm. (A) A single representative field of view is shown from one well. DAPI 833 
and ERK1/2 images were used to define nuclear and cytoplasmic regions, 834 
respectively, and GFP fluorescence was recorded from each region (as indicated in 835 
the inset screengrab showing automated cell definition), accepting >70 AFU per cell 836 
as positively transfected. (B) Plots of single cell data show a frequency histogram of 837 
nuclear : cytoplasmic GFP fluorescence (left panel) indicating a bimodal distribution 838 
of HSF1, which is unaffected by S326A/E mutation. The right hand panel shows a 839 
comparison of whole cell GFP fluorescence in the same cell populations versus 840 
nucleo-cytoplasmic distribution, indicating that the bimodal distribution is apparent 841 
across a 10-fold difference in HSF1-GFP levels, and is again unaffected by S326A/E 842 
substitution. 843 
 844 
 845 
 846 
 847 
 848 
  849 
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Table 1.  Phosphopeptides identified by liquid chromatography tandem mass 
spectrometry after 60-min incubation of recombinant human HSF1 (1.0 μg) 
with p38 MAPKα or p38 MAPKδ (0.06 mU/μl), followed by SDS/PAGE 
separation, and in-gel tryptic digestion. 
 
p38 MAPKα + HSF1 
Peptide sequence 
 
 
Phospho-S 
 
M (calc.) 
 
M (expt.) 
K.EEPPS303PPQS307PR.V  
 
R.VKEEPPS303PPQS307PR.V 
 
R.VEEASPGRPSSVDTLLS326PTALIDSILR.E
S303/307 
 
S303/307 
 
S326 
 
1299.5496 
 
1526.7130 
 
2902.4689 
1299.5487 
 
1526.7121 
 
2902.4659
p38 MAPKδ + HSF1 
Peptide sequence 
 
 
Phospho-S 
 
M (calc.) 
 
M (expt.) 
K.EEPPS303PPQS307PR.V  
 
R.VKEEPPS303PPQS307PR.V 
 
R.VEEASPGRPSSVDTLLS326PTALIDSILR.E
S303/307 
 
S303/307 
 
S326 
1299.5496 
 
1526.7130 
 
2902.4689 
1299.5493 
 
1526.7121 
 
2902.4683
 
